【香港記事】香港COVID19死亡新增比例的比较高的原因

我利用MSN资料，计算3月9日的死亡和新增的比例 = 291 （death）/ 31402 （new case) =0.92%。 其他地方的death rate是和流感差不多的，在0.1-0.19之间。

我们从数据了解一下原因吧： 有则COVID19的报道：醫管局總3月9日公布，3月8日新增196名新冠肺炎病人離世，再創新高。涉及127男、69女，年齡介乎24至107歲。當中24歲男病人來自院舍，本身有先天性遺傳病。死者之中113人來自院舍；148人無接種任何新冠疫苗，34人接種一針、12人接種兩針、2人接種三針疫苗。185人是65歲或以上長者。（1）哪，我早前提过打疫苗的重要性，148+34+12 = 194。 死亡的而没完成3針的疫苗有98%。（當然，都可以由其他角度去解析） 

 如果怕mRNA疫苗的副作用，同医生討論吓，如果医生認為科興可以，ie同意，就打科興啦。祝各位身體健康。 

 （1） https://www.msn.com/zh-hk/news/localnews/%e7%ac%ac5%e6%b3%a2%e7%96%ab%e6%83%85%ef%bd%9c%e5%a2%9e196%e5%90%8d%e7%97%85%e4%ba%ba%e9%9b%a2%e4%b8%96%e5%89%b5%e6%96%b0%e9%ab%98%e4%bb%8b%e4%b9%8e24%e8%87%b3107%e6%ad%b2-%e8%bf%bd%e5%8a%a098%e4%ba%ba%e6%9f%93%e7%96%ab%e4%ba%a1/ar-AAUVndM?li=BBqiXNi (2) https://www.bing.com/search?q=%E6%AD%BB%E4%BA%A1+%E6%96%B0%E5%86%A0%E8%82%BA%E7%82%8E+&form=PRHKZH&httpsmsn=1&msnews=1&refig=612c1a37835946f6ba88090dd89415f0&sp=-1&pq=%E6%AD%BB%E4%BA%A1+%E6%96%B0%E5%86%A0%E8%82%BA%E7%82%8E+&sc=0-8&qs=n&sk=&cvid=612c1a37835946f6ba88090dd89415f0

BioNtech COVID19 疫苗 近期资料 10-05-2021

開發首支Covid-19疫苗的德國BioNTech SE公司負責人表示，到2022年年中，可能需要一種新的配方來防止病毒的未來突變。

The head of BioNTech SE that developed the first Covid-19 vaccine, said a new formula is likely to be needed by mid-2022 to protect against future mutations of the virus. (Bloomberg; October 3, 2021) 

輝瑞公司/BioNTech SE疫苗在預防冠狀病毒感染方面的有效性從第二次劑量后六個月的88%下降到47%. 因此，可能需要第三剂。

The effectiveness of the Pfizer Inc /BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after taking the second dose, thus there may be a need for booster shots. (Reuters; October 5, 2021) 

歐盟藥品監管機構表示，免疫系統衰弱的人應該從輝瑞-BioNTech或Moderna接受第三劑COVID-19疫苗，但由成員國來決定。

The European Union's drugs regulator said on Monday people with weakened immune systems should get a third dose of a COVID-19 vaccine from Pfizer-BioNTech or Moderna, but left it to member states to decide if the wider population should have a booster. (Reuters; October 4, 2021) 

Merck/Ridgeback Biotherapeutics 宣佈了關於其口服抗病毒藥物molnupiravir的第三階段研究的中期數據。該藥物可使輕度或中度COVID-19的非住院成人患者住院或死亡的風險降低約50%。之后，BioNTech的股价大跌，我不明白，因为，molnupiravir是治疗用，而BioNTech是预防，两者是不同的东西。如果，利用monupiravir来预防，那么，用者可能每天都要服用，相当麻烦。如果，阁下有高见，请分享一下。谢谢

Merck/Ridgeback Biotherapeutics announced positive interim data from a phase III study on their oral antiviral medicine, molnupiravir. The medicine reduced the risk of hospitalization or death by approximately 50% in non-hospitalized adult patients with mild or moderate COVID-19. (ZACKS; October 4, 2021)  (Merck is supposed for treatment, while vaccine is for prevention. If someone uses Merck's for prevention (as an oral vaccine) then someone may need to take it daily. Do you think if this is quite troublesome? I don't understand how Merck's medicine can affect BioNTech's stock value. If you have the answer, please let me know.)

FDAfull批准16歲及以上人群用輝瑞/BioNTech疫苗。但他們尚未完全批准將其用作第3次注射。相反，FDA在緊急使用授權下批准了輝瑞的第3次注射，並批准了尚未申請的全部生物製劑許可證（BLA）。FDA希望以色列提供軍事人員的數據可以澄清接受輝瑞/BioNTechCOVID-19第3次注射对年輕人患心肌炎症的風險（安全性度）。

FDA granted full approval for the Pfizer/BioNTech vaccine for people age 16 and older but they have not yet given full approval for its use as a booster shot. Instead, the FDA approved Pfizer's booster under an emergency use authorization with approval on the full biologics license application (BLA) still pending. FDA are hoping data on Israeli military personnel can help clarify the risk of heart muscle inflammation in younger people who have received Pfizer/BioNTech COVID-19 booster shots. (Reuters; October 1, 2021)

以下是BioNTechCOVID19疫苗的供应分配：

Here tells where BioNTech's vaccine goes:

 

本来，中國应该在7月前批准BioNtech的疫苗。但中國研发的疫苗在預防住院治療方面是有效的，而对Delta變種BioNtech的療效降低到64%。另一方面，中國製藥商正在開發自己的mRNA疫苗。The Wall Street Jounral认为：這些因素可能導致BioNtech疫苗審批的延遲。

China was expected to approve the BioNTech vaccine, by July. Chinese vaccines have proven effective at preventing hospitalizations, while the Delta variant cuts BioNTech’s efficacy down to 64%. On the other hand, Chinese drug makers are developing their own mRNA vaccines. These factors may cause the delay for the BioNTech vaccine approval. (The Wall Street Journal; August 27, 2021)